| Literature DB >> 32853849 |
Jing Tang1, Shu-Xia Zhang1, Jing Zhang1, Xi-Yan Li1, Jian-Fang Zhou1, Shu-Mei Zou1, Hong Bo1, Li Xin1, Lei Yang1, Jia Liu1, Wei-Juan Huang1, Jie Dong1, Da-Yan Wang2.
Abstract
Human infections with highly pathogenic avian influenza (HPAI) H7N9 virus were detected in late 2016. We examined the drug resistance profile of 30 HPAI H7N9 isolates from Mainland of China (2016-2019). Altogether, 23% (7/30) carried neuraminidase inhibitors (NAIs) - resistance mutations, and 13% (4/30) displayed reduced susceptibility to NAIs in neuraminidase (NA) inhibition test. An HPAI H7N9 reassortment virus we prepared was passaged with NAIs for 10 passages. Passage with zanamivir induced an E119G substitution in NA, whereas passage with oseltamivir induced R292K and E119V substitutions that simulated that seen in oseltamivir -treated HPAI H7N9 cases, indicating that the high frequency of resistant strains in the HPAI H7N9 isolates is related to NAIs use. In presence of NAIs, R238I, A146E, G151E and G234T substitutions were found in HA1 region of HA. No amino acid mutations were found in the internal genes of the recombinant virus.Entities:
Keywords: Drug resistance; Highly pathogenic avian influenza H7N9; Influenza virus; Neuraminidase inhibitors
Mesh:
Substances:
Year: 2020 PMID: 32853849 DOI: 10.1016/j.virol.2020.07.018
Source DB: PubMed Journal: Virology ISSN: 0042-6822 Impact factor: 3.616